Global Gastrointestinal Stromal Tumor Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Gastrointestinal Stromal Tumor Market Insights, Forecast to 2034
Gastrointestinal stromal tumors (GISTs) start in special cells in the wall of the gastrointestinal (GI) tract, also known as the digestive tract.
Market Analysis and InsightsGlobal Gastrointestinal Stromal Tumor Market
Global Gastrointestinal Stromal Tumor market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Gastrointestinal Stromal Tumor industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as pathologists. Until now, the role of radiotherapy in treatment of gastrointestinal stromal tumor remains decisively unestablished. For being inoperable, patients suffering from this malignant tumor opt for symptomatic treatments such as conventional chemotherapy.
Report Covers
This report presents an overview of global Gastrointestinal Stromal Tumor market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Gastrointestinal Stromal Tumor market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Novartis
Sun Pharmaceutical
Pfizer
Bayer Aktiengesellschaft
NATCO Pharma
Segment by Type
Stomach
Small Intestine
Others
Hospitals
Clinics
Specialized Cancer Treatment Centers
Other End Users
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Gastrointestinal Stromal Tumor introduction, etc. Gastrointestinal Stromal Tumor Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Gastrointestinal Stromal Tumor
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Gastrointestinal Stromal Tumor Market
Global Gastrointestinal Stromal Tumor market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Gastrointestinal Stromal Tumor industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as pathologists. Until now, the role of radiotherapy in treatment of gastrointestinal stromal tumor remains decisively unestablished. For being inoperable, patients suffering from this malignant tumor opt for symptomatic treatments such as conventional chemotherapy.
Report Covers
This report presents an overview of global Gastrointestinal Stromal Tumor market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Gastrointestinal Stromal Tumor market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Novartis
Sun Pharmaceutical
Pfizer
Bayer Aktiengesellschaft
NATCO Pharma
Segment by Type
Stomach
Small Intestine
Others
Segment by Application
Hospitals
Clinics
Specialized Cancer Treatment Centers
Other End Users
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Gastrointestinal Stromal Tumor introduction, etc. Gastrointestinal Stromal Tumor Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Gastrointestinal Stromal Tumor
Chapter 13Methodology and Data Sources adopted by MRAResearch